Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118404 · ClinicalTrials.gov registry record · Phase 3
Cognitive Therapy for Recurrent Depression
A Phase 3 study of Depression, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
- 2
- Study locations
NCT00118404: Completed Phase 3 study of Depression, sponsored by University of Texas Southwestern Medical Center.
NCT00118404 is a Phase 3 study of Depression that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 523 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (33% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118404, a Phase 3 study of Depression, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.
Primary Outcome
Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment LIFE-PSR Scale: 1. = No residual symptoms, no current evidence of the disorder. 2. = Mild symptoms 3. = Considerably less psychopathology than full criteria with no more than moderate impairment 4. = Does not meet full criteria but has major symptoms of impairme
Conditions Studied
Interventions
- BEHAVIORAL Continuation phase cognitive therapy
- DRUG Continuation phase fluoxetine
- OTHER Continuation phase pill placebo
- BEHAVIORAL Acute phase cognitive therapy
Study Locations (2)
Pennsylvania
- University of Pittsburgh Medical Center Western Psychiatric Institute and Clinic - Pittsburgh
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2000-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00118404 record still lists
NCT00118404 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, below the 785-participant average among 679 other Depression trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Continuation phase cognitive therapy is the first listed.
NCT00118404 reports a single indexed study location in Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00118404 about?
NCT00118404 is a clinical study titled "Cognitive Therapy for Recurrent Depression". This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.
What is the current status of trial NCT00118404?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2000-03. Estimated completion is 2008-07.
What conditions does trial NCT00118404 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00118404?
The interventions under investigation include: Continuation phase cognitive therapy (BEHAVIORAL), Continuation phase fluoxetine (DRUG), Continuation phase pill placebo (OTHER), Acute phase cognitive therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00118404?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00118404 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00118404's enrollment target sits among peer trials
523 75th of 679 higher than 605 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia